AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Dynavax to Present at 2025 Wells Fargo Healthcare Conference
ByAinvest
Wednesday, Aug 27, 2025 4:07 pm ET1min read
Dynavax Technologies Corporation will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd. The Company's presentations will be webcast on its website. Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect against infectious diseases. Its marketed products include HEPLISAV-B vaccine and CpG 1018 adjuvant.
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd. The event will be webcast on the company's website. Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to protect against infectious diseases. Its current marketed products include HEPLISAV-B vaccine and CpG 1018 adjuvant.The company's participation in the conference follows recent positive topline results from Part 1 of its Phase 1/2 clinical trial of Z-1018, an investigational shingles vaccine candidate [2]. The trial demonstrated robust immune responses and a favorable tolerability profile, with Z-1018 achieving a 100% humoral vaccine response rate compared to the currently licensed shingles vaccine, Shingrix. Dynavax has selected the 100 mcg dose of gE antigen, adjuvanted with CpG 1018 and alum, and using an 8-week dosing interval, to advance into Part 2 of the Phase 1/2 trial in adults 70 years of age and older [2].
Dynavax's participation in the Wells Fargo Healthcare Conference provides an opportunity for investors and financial professionals to gain insights into the company's latest developments and future prospects. The company's Chief Executive Officer, Ryan Spencer, and Chief Medical Officer, Robert Janssen, will likely discuss the potential of Z-1018 to disrupt the multi-billion-dollar shingles vaccine market and the company's broader vaccine pipeline [2].
References:
[1] https://www.stocktitan.net/news/DVAX/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-sh60gajk3qr5.html
[2] https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet